Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy.
Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016. In June, the EMA’s Committee for Medicinal Products for Human Use (or CHMP) adopted a negative opinion of eteplirsen.
Sarepta had requested a reexamination of the opinion. On September 21, the company announced that the CHMP had confirmed its negative opinion of the drug’s application.
After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October. Sarepta Therapeutics stock has been in a downtrend in the last two weeks and reached its current ~$126.00 level in October.
The enterprise value of Sarepta Therapeutics is $8.2 billion, and its enterprise-value-to-revenue ratio is 33.97. Its price-to-sales ratio is 33.67, and its price-to-book ratio is 11.61. Sarepta’s price-to-book ratio stands at 11.45.
The price-to-book ratios of Sarepta’s peers Alnylam Pharmaceuticals (ALNY), Alexion Pharmaceuticals (ALXN), Biogen (BIIB), and Gilead Sciences (GILD) stand at 5.02, 3.15, 5.70, and 4.48, respectively.
In the final part of this series, we’ll see how analysts view Sarepta Therapeutics stock.